SCHEMBL6775908

SCHEMBL6775908

OCCNc1nncc(N2CC=C(c3ccccc3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 5/20 0.42
HSD17B10 Q99714 3/20 0.42
HPGD P15428 3/20 0.42
ALOX15 P16050 3/20 0.42
MAPT P10636 2/20 0.42
HTR1A P08908 3/20 0.41
TSHR P16473 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GBA1 P04062 2/20 0.38
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415027 0.77 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10HPGDALOX15
SCHEMBL1089521 0.73 CXCR4 (0.58) ALDH1A1KDM4EHSD17B10HPGDALOX15
SCHEMBL13650808 0.72 PIK3CA (0.43) ALDH1A1KDM4EHSD17B10HPGDALOX15
SCHEMBL4418202 0.72 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10HPGDALOX15
SCHEMBL11340503 0.71 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL3310965 0.63 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10ALOX15MAPT
SCHEMBL31582428 0.63 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL2323024 0.63 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10HPGDSMN1; SMN2
SCHEMBL9726233 0.62 SIGMAR1 (0.61) HTR1ASIGMAR1
Hydrochloric Acid SCHEMBL1596638 0.61 DRD4 (0.50) ALDH1A1ALOX15MAPTHTR1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 ALDH1A1 2009/4885KDM4E 2735/4885HSD17B10 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.